ENETS 2024 Daily highlight 2

Prof Alain Hendlisz, Associate Head of the Department of GI Oncology at Hospital Universitaire de Bruxelles, provides insights from the first day of the ENETS 2024 meeting.

The first study, by Dazari et al. from the MD Anderson Cancer Center, explores the combination of lenvatinib and everolimus in a phase II non-randomised trial. It demonstrated a remarkable 40% response rate and a median PFS of 13 months, albeit with some side effects such as asthenia and diarrhoea.

The second study, presented by J. Molina-Cerrillo and colleagues from Madrid, investigates the combination of cabozantinib and atezolizumab in various subgroups of patients. It reveals varying response rates across subgroups, suggesting limited added value over cabozantinib alone.

An intriguing phase 1 study, presented by Capdevila et al. from Madrid, introduces BI-764532, an antibody-drug conjugate targeting DLL3 in neuroendocrine carcinoma. The study demonstrated a remarkable 22% response rate and a 22% disease control rate, offering promising prospects in phase 1.

Lastly, De Mestier et al. presented a study on phenotypic changes induced by temozolomide in well-differentiated GEP-NETs, akin to changes observed in glioblastoma and colorectal cancer, suggesting potential combined treatment strategies involving temozolomide and immunotherapy, presenting a novel avenue for addressing the refractory nature of these tumours to immunotherapy.